Terms: = Kidney tumors AND Nuclear matrix protein 22 AND Diagnosis
6 results:
1. Use of the nuclear matrix protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma.
Xia CS; Fan CH; Su M; Wang QS; Bao HZ
Dis Markers; 2020; 2020():3424039. PubMed ID: 32454904
[TBL] [Abstract] [Full Text] [Related]
2. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract] [Full Text] [Related]
3. Long-term outcomes in a high-risk bladder cancer screening cohort.
Starke N; Singla N; Haddad A; Lotan Y
BJU Int; 2016 Apr; 117(4):611-7. PubMed ID: 25891519
[TBL] [Abstract] [Full Text] [Related]
4. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract] [Full Text] [Related]
5. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract] [Full Text] [Related]
6. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract] [Full Text] [Related]
